Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Durable responses after CD19 CAR-T plus ibrutinib in CLL

Alexandre Hirayama • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia CAR-T Ibrutinib

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses responses after CD19-specific CAR T-cell therapy with concurrent ibrutinib in patients with chronic lymphocytic leukemia (CLL) after prior ibrutinib failure. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Alexandre Hirayama

Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy 0:59
Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy
Alexandre Hirayama • 2 Jul 2019
Recent publication on the impact of response to lymphodepletion on PFS in NHL 1:31
Recent publication on the impact of response to lymphodepletion on PFS in NHL
Alexandre Hirayama • 20 Jun 2019

Related Videos

The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals